N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A

Maurizio Bifulco, Alba D'Alessandro, Simona Paladino, Anna M. Malfitano, Maria Notarnicola, Maria G. Caruso, Chiara Laezza

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hutchinson-Gilford progeria syndrome is caused by mutations in the lamin A/C gene that lead to expression of a truncated, permanently farnesylated prelamin A variant called progerin. The accumulation of progerin at the nuclear envelope causes mis-shapen nuclei and results in progeroid syndromes. Previous studies in cells from individuals with Hutchinson-Gilford progeria syndrome have shown that blocking of farnesylation of prelamin A ameliorates the nuclear shape abnormalities. Here we observed that an inhibitor of farnesyl diphosphate synthase, N6-isopentenyladenosine, impeded the farnesylation of prelamin A, causing a decrease in the frequency of nuclear shape abnormalities and redistribution of prelamin A away from the inner nuclear envelope. A combination of lovastatin and N6-isopentenyladenosine significantly improved nuclear shape in fibroblast cell lines from atypical progeria patients. These findings establish a paradigm for ameliorating the most obvious cellular pathology in lamin-related progeroid syndromes, and suggest a potential strategy for treating children with Hutchinson-Gilford progeria syndrome.

Original languageEnglish
Pages (from-to)6223-6232
Number of pages10
JournalFEBS Journal
Volume280
Issue number23
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Isopentenyladenosine
Progeria
Prenylation
Fibroblasts
Nuclear Envelope
Geranyltranstransferase
Lamins
Lamin Type A
Lovastatin
Pathology
Genes
Cells
Cell Line
Mutation
prelamin A

Keywords

  • farnesyl diphosphate synthase
  • Hutchinson-Gilford progeria syndrome
  • mevalonate pathway
  • N6-isopentenyladenosine
  • prelamin A

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A. / Bifulco, Maurizio; D'Alessandro, Alba; Paladino, Simona; Malfitano, Anna M.; Notarnicola, Maria; Caruso, Maria G.; Laezza, Chiara.

In: FEBS Journal, Vol. 280, No. 23, 12.2013, p. 6223-6232.

Research output: Contribution to journalArticle

Bifulco, Maurizio ; D'Alessandro, Alba ; Paladino, Simona ; Malfitano, Anna M. ; Notarnicola, Maria ; Caruso, Maria G. ; Laezza, Chiara. / N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A. In: FEBS Journal. 2013 ; Vol. 280, No. 23. pp. 6223-6232.
@article{33d1ca9a76d740829a5474d093841bbd,
title = "N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A",
abstract = "Hutchinson-Gilford progeria syndrome is caused by mutations in the lamin A/C gene that lead to expression of a truncated, permanently farnesylated prelamin A variant called progerin. The accumulation of progerin at the nuclear envelope causes mis-shapen nuclei and results in progeroid syndromes. Previous studies in cells from individuals with Hutchinson-Gilford progeria syndrome have shown that blocking of farnesylation of prelamin A ameliorates the nuclear shape abnormalities. Here we observed that an inhibitor of farnesyl diphosphate synthase, N6-isopentenyladenosine, impeded the farnesylation of prelamin A, causing a decrease in the frequency of nuclear shape abnormalities and redistribution of prelamin A away from the inner nuclear envelope. A combination of lovastatin and N6-isopentenyladenosine significantly improved nuclear shape in fibroblast cell lines from atypical progeria patients. These findings establish a paradigm for ameliorating the most obvious cellular pathology in lamin-related progeroid syndromes, and suggest a potential strategy for treating children with Hutchinson-Gilford progeria syndrome.",
keywords = "farnesyl diphosphate synthase, Hutchinson-Gilford progeria syndrome, mevalonate pathway, N6-isopentenyladenosine, prelamin A",
author = "Maurizio Bifulco and Alba D'Alessandro and Simona Paladino and Malfitano, {Anna M.} and Maria Notarnicola and Caruso, {Maria G.} and Chiara Laezza",
year = "2013",
month = "12",
doi = "10.1111/febs.12544",
language = "English",
volume = "280",
pages = "6223--6232",
journal = "FEBS Journal",
issn = "1742-464X",
publisher = "Wiley-Blackwell",
number = "23",

}

TY - JOUR

T1 - N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A

AU - Bifulco, Maurizio

AU - D'Alessandro, Alba

AU - Paladino, Simona

AU - Malfitano, Anna M.

AU - Notarnicola, Maria

AU - Caruso, Maria G.

AU - Laezza, Chiara

PY - 2013/12

Y1 - 2013/12

N2 - Hutchinson-Gilford progeria syndrome is caused by mutations in the lamin A/C gene that lead to expression of a truncated, permanently farnesylated prelamin A variant called progerin. The accumulation of progerin at the nuclear envelope causes mis-shapen nuclei and results in progeroid syndromes. Previous studies in cells from individuals with Hutchinson-Gilford progeria syndrome have shown that blocking of farnesylation of prelamin A ameliorates the nuclear shape abnormalities. Here we observed that an inhibitor of farnesyl diphosphate synthase, N6-isopentenyladenosine, impeded the farnesylation of prelamin A, causing a decrease in the frequency of nuclear shape abnormalities and redistribution of prelamin A away from the inner nuclear envelope. A combination of lovastatin and N6-isopentenyladenosine significantly improved nuclear shape in fibroblast cell lines from atypical progeria patients. These findings establish a paradigm for ameliorating the most obvious cellular pathology in lamin-related progeroid syndromes, and suggest a potential strategy for treating children with Hutchinson-Gilford progeria syndrome.

AB - Hutchinson-Gilford progeria syndrome is caused by mutations in the lamin A/C gene that lead to expression of a truncated, permanently farnesylated prelamin A variant called progerin. The accumulation of progerin at the nuclear envelope causes mis-shapen nuclei and results in progeroid syndromes. Previous studies in cells from individuals with Hutchinson-Gilford progeria syndrome have shown that blocking of farnesylation of prelamin A ameliorates the nuclear shape abnormalities. Here we observed that an inhibitor of farnesyl diphosphate synthase, N6-isopentenyladenosine, impeded the farnesylation of prelamin A, causing a decrease in the frequency of nuclear shape abnormalities and redistribution of prelamin A away from the inner nuclear envelope. A combination of lovastatin and N6-isopentenyladenosine significantly improved nuclear shape in fibroblast cell lines from atypical progeria patients. These findings establish a paradigm for ameliorating the most obvious cellular pathology in lamin-related progeroid syndromes, and suggest a potential strategy for treating children with Hutchinson-Gilford progeria syndrome.

KW - farnesyl diphosphate synthase

KW - Hutchinson-Gilford progeria syndrome

KW - mevalonate pathway

KW - N6-isopentenyladenosine

KW - prelamin A

UR - http://www.scopus.com/inward/record.url?scp=84888290512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888290512&partnerID=8YFLogxK

U2 - 10.1111/febs.12544

DO - 10.1111/febs.12544

M3 - Article

VL - 280

SP - 6223

EP - 6232

JO - FEBS Journal

JF - FEBS Journal

SN - 1742-464X

IS - 23

ER -